Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
Canada flag Canada · Delayed Price · Currency is CAD
7.32
-0.14 (-1.88%)
Aug 1, 2025, 3:59 PM EDT

Eupraxia Pharmaceuticals Company Description

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need.

The company’s proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.

Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery.

The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.

Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Eupraxia Pharmaceuticals Inc.
CountryCanada
Founded2011
IndustryBiotechnology
SectorHealthcare
Employees33
CEOJames Helliwell

Contact Details

Address:
2067 Cadboro Bay Road
Victoria, British Columbia V8R 5G4
Canada
Phone250-590-3968
Websiteeupraxiapharma.com

Stock Details

Ticker SymbolEPRX
ExchangeToronto Stock Exchange
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberCA29842P1053
SIC Code2836

Key Executives

NamePosition
Dr. James A. Helliwell FRCPC, M.D.Chief Executive Officer and Director
Dr. Amanda Malone Ph.D.Chief Scientific Officer and Chief Operating Officer
Paul Anthony Brennan B.Sc., M.Sc.Chief Business Officer
Dr. Mark M. Kowalski M.D., Ph.D.Chief Medical Officer
Alexander John Rothwell Eng., M.B.A.Chief Financial Officer